Overall, combined AURKB and MEK1/2 inhibition decreases cell growth 64–87% (Figure 4), suggesting a potential benefit of combined MEK1/2 and AURKB inhibition in BRAF-mutant thyroid cancer cell lines. The gene discussed is BRAF; the disease is thyroid gland carcinoma.